Scopus BioPharma (SCPS) Competitors $0.0003 0.00 (0.00%) As of 10:09 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsShort InterestTrendsBuy This Stock SCPS vs. NAVB, OBSV, SYRS, SMFL, VRPX, STAB, EVLO, CMRA, GNCAQ, and GNCAShould you be buying Scopus BioPharma stock or one of its competitors? The main competitors of Scopus BioPharma include Navidea Biopharmaceuticals (NAVB), ObsEva (OBSV), Syros Pharmaceuticals (SYRS), Smart for Life (SMFL), Virpax Pharmaceuticals (VRPX), Statera Biopharma (STAB), Evelo Biosciences (EVLO), Comera Life Sciences (CMRA), Genocea Biosciences (GNCAQ), and Genocea Biosciences (GNCA). These companies are all part of the "pharmaceutical products" industry. Scopus BioPharma vs. Its Competitors Navidea Biopharmaceuticals ObsEva Syros Pharmaceuticals Smart for Life Virpax Pharmaceuticals Statera Biopharma Evelo Biosciences Comera Life Sciences Genocea Biosciences Genocea Biosciences Navidea Biopharmaceuticals (NYSE:NAVB) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, analyst recommendations, risk, valuation, dividends, media sentiment and institutional ownership. Does the media favor NAVB or SCPS? In the previous week, Navidea Biopharmaceuticals' average media sentiment score of 0.00 equaled Scopus BioPharma'saverage media sentiment score. Company Overall Sentiment Navidea Biopharmaceuticals Neutral Scopus BioPharma Neutral Do insiders & institutionals believe in NAVB or SCPS? 0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are owned by insiders. Comparatively, 5.1% of Scopus BioPharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has preferable earnings and valuation, NAVB or SCPS? Scopus BioPharma has lower revenue, but higher earnings than Navidea Biopharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNavidea Biopharmaceuticals$8.13K6.16-$15.18MN/AN/AScopus BioPharmaN/AN/A-$11.61MN/AN/A Is NAVB or SCPS more profitable? Company Net Margins Return on Equity Return on Assets Navidea BiopharmaceuticalsN/A N/A N/A Scopus BioPharma N/A N/A N/A Which has more risk and volatility, NAVB or SCPS? Navidea Biopharmaceuticals has a beta of 1.99, indicating that its share price is 99% more volatile than the S&P 500. Comparatively, Scopus BioPharma has a beta of -0.16, indicating that its share price is 116% less volatile than the S&P 500. SummaryNavidea Biopharmaceuticals beats Scopus BioPharma on 4 of the 5 factors compared between the two stocks. Get Scopus BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for SCPS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SCPS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SCPS vs. The Competition Export to ExcelMetricScopus BioPharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$13K$840.76M$5.78B$10.19BDividend YieldN/A4.84%5.73%4.61%P/E RatioN/A1.1474.8626.40Price / SalesN/A26.51540.53124.73Price / CashN/A19.5625.8129.91Price / BookN/A6.6613.256.28Net Income-$11.61M-$4.13M$3.29B$270.38M7 Day PerformanceN/A2.15%0.47%2.70%1 Month PerformanceN/A8.15%4.60%5.99%1 Year PerformanceN/A26.42%73.42%25.94% Scopus BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SCPSScopus BioPharmaN/A$0.00flatN/AN/A$13KN/A0.009Gap DownNAVBNavidea BiopharmaceuticalsN/A$0.00flatN/A-50.0%$50K$8.13K0.0010High Trading VolumeOBSVObsEvaN/A$0.00flatN/AN/A$39KN/A0.0050SYRSSyros Pharmaceuticals4.2713 of 5 stars$0.00-50.0%$1.00+90,809.1%-99.9%$30K$386K0.00120Short Interest ↓Gap DownSMFLSmart for LifeN/A$0.00+22.7%N/A-100.0%$19K$11.11M0.00110Gap UpVRPXVirpax Pharmaceuticals0.1723 of 5 stars$0.01flatN/AN/A$14KN/A0.007Gap DownSTABStatera BiopharmaN/A$0.00+100.0%N/AN/A$11KN/A0.0020Gap UpHigh Trading VolumeEVLOEvelo BiosciencesN/A$0.00flatN/AN/A$9KN/A0.00120CMRAComera Life SciencesN/A$0.00flatN/AN/A$6K$1.00M0.002GNCAQGenocea BiosciencesN/AN/AN/AN/A$6KN/A0.0070GNCAGenocea BiosciencesN/AN/AN/AN/A$6K$1.91M0.0070News Coverage Related Companies and Tools Related Companies Navidea Biopharmaceuticals Competitors ObsEva Competitors Syros Pharmaceuticals Competitors Smart for Life Competitors Virpax Pharmaceuticals Competitors Statera Biopharma Competitors Evelo Biosciences Competitors Comera Life Sciences Competitors Genocea Biosciences Competitors Genocea Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SCPS) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Scopus BioPharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Scopus BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SCPS Stock Alerts